- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Products
t2cure’s pipeline is well advanced and is built on clinical studies completed or currently being conducted by the founders in collaboration with other academic clinical centers.
In the cardiac indications, t2cure is on the verge of entering Phase III clinical trials for severe infarcts based on the results of the TOPCARE-AMI and REPAIR-AMI studies. Phase I/II clinical proof-of-concept studies have also been completed in chronic heart diseases: ischemic heart failure and non-ischemic dilated cardiomyopathy. In the chronic indications, t2cure will focus on the development of its bone marrow-derived cell therapy enhanced by a patent-protected preceding shock wave application to the chronic ischemic heart.
In the peripheral vascular area, a phase I/II proof-of-concept study was completed in the indication peripheral artery disease, including PAOD and thromboangiitis obliterans patients. t2cure will focus on the orphan indication thromboangiitis obliterans for further development.
